Is there a role for PET-CT-directed therapy in DLBCL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Judith Trotman, Concord Repatriation General Hospital, Sydney, AU. We asked, Is there a role for positron emission tomography (PET)-computed tomography-directed therapy in diffuse large B-cell lymphoma (DLBCL)?

In this podcast, Trotman starts by explaining the role of PET in staging of DLBCL. She adds that PET has excellent sensitivity in identifying bone marrow involvement in DLBCL. She then explains the importance of interim PET assessment, which identifies chemosensitivity with a high degree of accuracy. Unfortunately, no effective alternative treatments are available for patients who remain interim PET-positive. Finally, she discusses end-of-treatment PET.